First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan

OBJECTIVE: Ascites in patients with decompensated cirrhosis can lead to abdominal distention and decrease quality of life. Tolvaptan, a vasopressin V2 receptor antagonist, is an effective agent in the treatment of ascites, whereas some patients are refractory to tolvaptan. The efficacy of transjugul...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuruya, Kota, Koizumi, Jun, Sekiguchi, Yuka, Ono, Shun, Sekiguchi, Tatsuya, Hara, Takuya, Mishima, Yusuke, Arase, Yoshitaka, Hirose, Shunji, Shiraishi, Koichi, Kagawa, Tatehiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124206/
https://www.ncbi.nlm.nih.gov/pubmed/37085275
http://dx.doi.org/10.1136/bmjgast-2023-001120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124206/
https://www.ncbi.nlm.nih.gov/pubmed/37085275
http://dx.doi.org/10.1136/bmjgast-2023-001120

Ejemplares similares